Hyperprogressive disease: recognizing a novel pattern to improve patient management
Stéphane Champiat, Roberto Ferrara, Christophe Massard et al. · Nature Reviews Clinical Oncology · 2018
Cited by 362 works. doi:10.1038/s41571-018-0111-2
Authors
- Stéphane Champiat
- Roberto Ferrara
- Christophe Massard
- Benjamin Besse
- Aurélien Marabelle
- Jean‐Charles Soria
- Charles Ferté
References
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- The blockade of immune checkpoints in cancer immunotherapy
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- PD-1 and Its Ligands in Tolerance and Immunity